Interpace Biosciences (IDXG) investor relations material

Executive summary

• Q1 2026 revenue was $9.0 million, down 22% year-over-year due to the loss of PancraGEN® reimbursement, but driven by 12% thyroid revenue growth and a 10% increase in thyroid test volume.

• Net income for Q1 2026 was $0.7 million, while income from continuing operations was $0.8 million.

• All Series C Preferred Stock was converted to common stock in January 2026, increasing outstanding shares to 27.7 million as of March 31, 2026.

• Transition to a thyroid-only diagnostics model improved operational efficiency and margin expansion.

• Gross margin expanded to 65% from 59% on a pro forma basis year-over-year.

Financial highlights

• Revenue for Q1 2026 was $9.0 million, down from $11.5 million in Q1 2025, but up 14% from $7.9 million pro forma.

• Gross profit for Q1 2026 was $5.9 million (65% margin), down from $7.4 million (64% margin) in Q1 2025, but up from 59% pro forma margin.

• Operating income from continuing operations was $1.1 million, up from $0.5 million pro forma in Q1 2025, but down from $1.8 million year-over-year.

• Adjusted EBITDA for Q1 2026 was $1.6 million, up from $0.8 million pro forma, but down from $2.1 million in Q1 2025.

• Cash and cash equivalents were $2.6 million at March 31, 2026, with $10.0 million in current assets and $4.0 million in current liabilities.

Outlook and guidance

• Current cash and forecasted receipts are expected to meet anticipated requirements for the next twelve months.

• Management is exploring strategic alternatives and additional funding sources, including equity and debt financings.

• The company aims to uplist its common stock to Nasdaq but provides no assurance of success.

• Reaffirmed 2026 guidance for 16% year-over-year thyroid revenue growth.

• Focus remains on scaling thyroid test volume, expanding the account base, and driving productivity through automation.